Consistently, in the SU2C dataset, the higher FN1 expression with a median threshold was significantly associated with therapy resistance as measured by time on treatment in all 56 patients with different metastasis combined, which was even more significant in patients with bone metastasis (Fig. 4 O). Here, FN1 is linked to bone metastasis.